News

Neuropore Therapies Awarded $4.8M Grant from The Michael J. Fox Foundation for Parkinson’s Research 
April 19, 2022

Neuropore Therapies, Inc., announced today that it received a grant from The Michael J. Fox Foundation (MJFF) for Parkinson’s research to support development of its TLR2 program.

Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement with UCB 
May 17, 2021

Neuropore Therapies, Inc. announced today that it has earned a milestone payment related to its collaboration with UCB and the evaluation of UCB0599 for the treatment of Parkinson’s Disease.

Neuropore Therapies Licenses Autophagy Modulators to Global Cancer Technology for Treatment of Cancers and Other Life-Threatening Diseases 
September 29, 2020

Neuropore Therapies, Inc. announced today that it has licensed two mechanistically distinct classes of potent, selective and brain penetrating modulators of mTOR–regulated autophagy to Global Cancer Technology.

Neuropore Therapies Receives Grant from The ALS AssociationFebruary 17, 2020

Neuropore Therapies, Inc., a clinical stage biopharmaceutical company announced today that it has been awarded a $500,000 grant from The ALS Association to support the preclinical evaluation and development of its leading Toll-Like Receptor 2 (TLR2) antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis. The grant has been made through the Association’s Lawrence and Isabel Barnett Drug Development Program.

Neuropore Therapies Completes Phase 1 Trial in Healthy Volunteers with NPT520-34 January 13, 2020

Neuropore Therapies, Inc., a clinical stage biopharmaceutical company announced today that it has successfully completed the Phase 1 clinical trial in healthy volunteers with NPT520-34.  NPT520-34 is a small molecule being developed for Parkinson’s disease and amyotrophic lateral sclerosis.

Neuropore Therapies Appoints Dr. Joseph S. McCracken to Board of Directors October 29, 2019

Neuropore Therapies, Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the underlying causes of neurodegenerative disease, announced today the appointment of Joseph S. McCracken, DVM, MS to its board of directors.

Neuropore Receives Orphan Drug Designation for NPT520-34 for the Treatment of Amyotrophic Lateral Sclerosis August 14, 2019

Neuropore Therapies, Inc. announced today that it has received orphan drug designation for NPT520-34 for the treatment of amyotrophic lateral sclerosis or ALS. The orphan drug designation will facilitate the development of NPT520-34 in the treatment of this debilitating medical condition for which limited treatments are available.

Neuropore Therapies and BenevolentAI Enter Strategic Collaboration to Discover Novel Therapeutics Through the Application of Artificial Intelligence August 5, 2019

Neuropore Therapies, Inc. announced today that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence. The molecular targets of interest are implicated in dysfunctions in proteostasis and can therefore be modulated to restore normal cellular protein clearance mechanisms. The collaboration aims to discover small molecule therapeutics for multiple targets.

UCB Initiates Phase 1b US-Based Multicenter Clinical Trial in Parkinson’s Disease Patients with UCB0599, a Compound Arising from the Neuropore-UCB Collaboration May 28, 2019

Neuropore Therapies, Inc. announced today that partner UCB initiated a multicenter clinical trial in Parkinson’s disease patients with UCB0599 in the United States of America.  UCB0599, an alpha-synuclein misfolding inhibitor, is a therapeutic candidate arising from the Neuropore-UCB collaboration.  Neuropore will receive a $5 million (USD) award as a result of achieving this milestone.

Neuropore Initiates Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson’s Disease and Amyotrophic Lateral Sclerosis May 8, 2019

Neuropore Therapies, Inc. announced today that it has initiated a Phase 1 clinical trial in healthy volunteers with NPT520-34. This Phase 1 study is designed to evaluate the safety, tolerability and pharmacokinetics of NPT520-34.

Neuropore Therapies Awarded Second Grant on its TLR2 Program from The Michael J. Fox Foundation for Parkinson’s Research January 4, 2018

Neuropore Therapies, Inc. has received a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.

Neuropore Therapies Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research January 30, 2017

Neuropore Therapies, Inc. has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.

Neuropore Therapies Announces Appointment of Dr. Errol De Souza as President and Chief Executive Officer January 23, 2017

Neuropore Therapies, Inc. announced today that Errol De Souza, Ph.D. has been appointed President and Chief Executive Officer effective immediately.

Neuropore Therapies (NPT) Announces Achievement of Key Program Milestone September 13, 2016

Based on promising findings from ongoing clinical and non-clinical studies, UCB awarded NPT a major program milestone of $5 million.

Neuropore publishes paper describing use of retinal imaging for evaluating potential therapies for Parkinson’s disease and other synucleinopathies August 4, 2016

The report in Scientific Reports describes findings that support the use of non-invasive retinal imaging in animal models as a tool to monitor the fate of α-synuclein accumulation in the CNS and to evaluate the effects of putative therapeutic agents targeting α-synuclein for Parkinson’s disease and other synucleinopathies

Neuropore Announces Successful Completion of Phase l with its Lead Compound NPT200-11 March 7, 2016

NPT200-11 was well tolerated in 55 volunteers after oral administration

Neuropore Therapies Commences Phase 1 Clinical Trials August 12, 2015

Neuropore Therapies Inc. commences Phase 1 clinical trials with NPT200-11; a potential new disease modifying treatment for Parkinson's Disease

Neuropore And UCB Enter Into World-Wide Collaboration And Agreement January 15, 2015

Companies collaborate in the development of a small molecule disease modifying treatment option for people living with Parkinson's disease

Completion Of A Study On Retinal Pathology In An Animal Model Of Parkinson's Disease April 8, 2014

Neuropore Therapies Inc. and collaborators at the University of California, San Diego complete a study on the progression of Parkinson's disease in Laboratory Animals Using Phoenix Research Labs' Retinal Imaging Technology.

Advancement Of NPT200-11 Into Preclinical Development January 30, 2014

NeuroPore Therapies, a San Diego based biopharmaceutical company dedicated to the discovery and development of novel therapeutics for neurodegenerative disorders, with support from the Michael J. Fox foundation, has initiated preclinical development of its lead compound for the treatment of Parkinson’s disease.